Berkeley Lights logo
Berkeley Lights BLI

Quarterly report 2023-Q2
added 08-14-2023

report update icon

Berkeley Lights Financial Ratios 2011-2026 | BLI

Annual Financial Ratios Berkeley Lights

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-1.2 -16.9 -67.1 - - - - - - - - -

P/S

1.5 14.2 43.4 - - - - - - - - -

EPS

-1.4 -1.1 -1.4 -7.5 -10.2 - - - - - - -

EV (Enterprise Value)

115 M 1.11 B 2.61 B -34.1 M -63.7 M - - - - - - -

EBITDA per Share

-1.29 -0.98 -1.13 - - - - - - - - -

EV/EBITDA

-16.9 -131.7 - - - - - - - - -

PEG

- 0.86 - - - - - - - - -

P/B

0.8 5.8 11.4 - - - - - - - - -

P/CF

-2.5 -22.8 -77.8 - - - - - - - - -

ROE %

-69.02 -34.45 -16.99 - - - - - - - - -

ROA %

-43.36 -24.97 -13.88 - - - - - - - - -

ROCE %

-69.03 -34.00 -16.50 - - - - - - - - -

Current Ratio

2.7 3.6 5.5 - - - - - - - - -

DSO

103.3 83.1 36.7 - - - - - - - - -

DIO

245.7 162.0 102.1 - - - - - - - - -

DPO

134.5 74.0 32.3 - - - - - - - - -

Operating Cycle

349.0 245.1 138.8 - - - - - - - - -

Cash Conversion Cycle

214.5 171.1 106.5 - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Berkeley Lights

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.51 -0.31 - -0.32 -0.38 -0.32 - -0.3 -0.27 -0.24 -0.19 -0.16 -4.25 -3.02 -1.42 -1.78 -2.43 -1.84 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.45 -0.27 - -0.28 -0.34 -0.29 - -0.28 -0.25 -0.21 - -0.13 -3.49 -2.27 - -1.01 -1.53 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-87.27 -56.88 -39.49 -48.75 -44.38 -37.45 -23.47 -28.42 -22.67 -19.91 -16.99 -16.17 -17.96 -20.27 -21.28 -17.14 -11.83 -4.45 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-54.33 -36.51 -27.59 -34.37 -31.96 -27.75 -18.01 -22.06 -18.15 -16.16 -13.88 -12.47 -13.00 -13.57 -10.76 -8.12 -4.72 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-84.12 -56.35 -39.27 -48.35 -43.81 -36.86 -23.02 -26.37 -20.64 -17.90 -11.67 -16.77 -18.54 -20.26 -11.79 -11.79 -6.69 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

2.7 2.1 2.7 3.1 3.4 3.7 3.6 3.7 4.6 5.0 5.5 5.5 5.5 5.5 2.8 2.8 2.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

128.1 107.6 - 72.6 75.1 98.6 - 83.4 85.8 71.9 54.3 64.8 111.7 73.8 51.2 54.4 36.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

495.0 577.5 - 224.6 229.7 216.1 - 132.0 164.5 162.4 - 186.7 279.5 218.9 - 163.9 149.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

203.0 243.4 - 117.5 121.1 116.0 - 110.3 109.6 77.0 - 59.0 88.3 80.8 - 74.0 67.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

623.1 685.0 - 297.2 304.8 314.7 - 215.4 250.3 234.3 54.3 251.5 391.2 292.7 51.2 218.3 185.7 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

420.1 441.6 - 179.7 183.7 198.7 - 105.1 140.7 157.3 54.3 192.5 302.9 211.8 51.2 144.3 118.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Berkeley Lights, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adagene Adagene
ADAG
$ 2.9 4.69 % $ 163 M chinaChina
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.24 -4.14 % $ 7.8 B australiaAustralia
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.57 -1.91 % $ 16.1 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 116.68 0.45 % $ 27.2 B germanyGermany
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 223.43 0.44 % $ 5 B danmarkDanmark
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.61 1.37 % $ 1.52 B britainBritain
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.19 -5.42 % $ 9.12 B israelIsrael
Beam Therapeutics Beam Therapeutics
BEAM
$ 29.29 0.91 % $ 2.41 B usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 69.61 6.15 % $ 9.31 B usaUSA
Biogen Biogen
BIIB
$ 176.68 1.06 % $ 25.7 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.11 1.11 % $ 4.36 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 3.06 1.66 % $ 908 M israelIsrael
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
$ 92.72 -0.54 % $ 96.9 B britainBritain
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA